BRD4 and cancer: Consistent with our results, Brd4 was also detected at human promoters following BD inhibition or mutation, which explains why BET degradation outperforms BET inhibition in preclinical cancer models (Bauer et al., 2021; Kanno et al., 2014; Winter et al., 2017).